EN DE
Watch Cellid Co. Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Cellid Co. Ltd (299660) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Cellid Co. Ltd stock KRW 1,528, price KRW 1,700, that is 10.1% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7299660001

CC Cellid Co. Ltd logo Thin data Nov 16, 2026

Cellid Co. Ltd

299660 · KQ

Expensive (fair value 10% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Mixed Growth (revenue 3y +164.1 %/yr in KRW) 
Mixed vs. peers (4/9) 
Fair value 1,528 KRW · Overvalued 
Quality 26/100 
Falling price (downtrend) 
Loss-making · -136.5% net margin (FY2025) 
Negative free cash flow 
Narrow moat 12/100
Thin data 
Estimate
Watch Cellid Co. Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

127,128 KRW 1,025 KRW Fair Value 1,528 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,025 KRW – 127,128 KRW · fair‑value band 1,146 KRW – 1,910 KRW · the 1,700 KRW price screens above the 1,528 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Cellid Co. in your weekly email

Every Wednesday you see whether Cellid Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.

Show moreShow less

It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens.

The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.

Stock analysis

Cellid Co. Ltd (299660) currently trades at 1,700 KRW, while our estimate is 1,528 KRW, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,146 KRW (bear) to 1,910 KRW (bull), the price of 1,700 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cellid Co. Ltd reported revenue of 8.8B KRW in FY2025 versus 909M KRW in FY2021, a compound +76.6%/yr. Reported net income was −12.1B KRW in FY2025.

Key figures

Market cap 52.9B KRW (≈ $39.8M) Micro · P/S ratio 13.9 · Net margin −137% · Return on equity −26.7% · Return on assets (EBIT) −19.8% (5-year average) · Operating margin −768% · Revenue (TTM) 4.2B KRW · Free cash flow −35.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 59% below its 52-week high and 66% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, 299660 screens richer than that median.

Fair Value

Bear 1,146 KRW Fair Value 1,528 KRW Bull 1,910 KRW
Price 1,700 KRW · Downside -10.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 84
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 8
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 23/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+112.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.1%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,431.2% (2021) → −128.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

299660 screens overvalued: fair value 10% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cellid Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −10.1% · Above median
Profitability
Return on assets −10.9% · Above median
Net margin (12 months) −136.5% · Bottom 25%
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.71× · Cheapest 25%
P/S (12 months) 12.69× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 2
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $945.53 $1,275 +35% vs 299660
Vertex Pharmaceuticals Incorporated VRTX $536.45 $587.62 +10% vs 299660
Samsung Biologics Co 207940 1,375,000 KRW 1,502,600 KRW +9% vs 299660
argenx SE ARGX $941.25 $908.40 −3% vs 299660
CSL Limited CSL A$199.85 A$186.49 −7% vs 299660
Moderna, Inc MRNA $196.79 $135.64 −31% vs 299660
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs 299660
Revolution Medicines, Inc RVMD $159.82 $83.12 −48% vs 299660
Celltrion, Inc 068270 215,000 KRW 74,945 KRW −65% vs 299660
Royalty Pharma plc RPRX $68.67 $19.01 −72% vs 299660

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cellid Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cellid Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/299660

Frequently asked questions

Is Cellid Co. Ltd (299660) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,528 KRW versus a price of 1,700 KRW, about 10% lower (overvalued).
What is the fair value of 299660?
Our estimate for Cellid Co. Ltd is 1,528 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,700 KRW.
What is the quality score of 299660?
Cellid Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cellid Co. Ltd (299660)?
We do not set a price target; the yardstick is our estimate of 1,528 KRW (as of Nov 16, 2026). Cautious scenario 1,146 KRW, optimistic scenario 1,910 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cellid Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 1,528 KRW, about 10% lower versus a price of 1,700 KRW (overvalued). Cautious scenario 1,146 KRW, optimistic scenario 1,910 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cellid Co. Ltd (299660)?
Cellid Co. Ltd reported trailing-twelve-month revenue of about 4.2B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Cellid Co. Ltd (299660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cellid Co. Ltd it is 1,528 KRW per share (as of Nov 16, 2026), against a price of 1,700 KRW.
Is Cellid Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 299660 trades above its calculated fair value: price 1,700 KRW, fair value 1,528 KRW, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 299660?
No. The price is what the market pays today (1,700 KRW); the fair value is what the company's own numbers justify (1,528 KRW). For Cellid Co. Ltd the two are 172.28 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cellid Co. Ltd worth?
The market values Cellid Co. Ltd at about 52.9B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,700 KRW; our models calculate a fair value of 1,528 KRW per share.
What do the bullish and bearish scenarios say about 299660?
Our models span a range for Cellid Co. Ltd: cautious scenario 1,146 KRW, base 1,528 KRW, optimistic 1,910 KRW per share (as of Nov 16, 2026, price 1,700 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cellid Co. Ltd (299660)?
Balance-sheet figures for Cellid Co. Ltd (as of Nov 16, 2026): return on equity −26.7%, debt of 0.18 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 299660 from its 52-week high?
Cellid Co. Ltd trades at 1,700 KRW, about 59% below its 52-week high of 4,110 KRW and 66% above the low of 1,025 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 1,528 KRW is for.
Which stocks are comparable to Cellid Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cellid Co. Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 1,700 KRW, calculated fair value 1,528 KRW (−10%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Cellid Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cellid Co. Ltd (299660)?
The closing price on Nov 19, 2026 was 1,700 KRW. Our estimate is 1,528 KRW, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cellid Co. Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Cellid Co. Ltd

How large is the market capitalisation of Cellid Co. Ltd (299660)?
The market capitalisation of Cellid Co. Ltd is 52.9B KRW (≈ $39.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cellid Co. Ltd (299660)?
The price-to-sales ratio of Cellid Co. Ltd is 13.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Cellid Co. Ltd (299660)?
The net margin of Cellid Co. Ltd is −137% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cellid Co. Ltd (299660)?
The return on equity (ROE) of Cellid Co. Ltd is −26.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cellid Co. Ltd (299660)?
On an EBIT basis the return on assets of Cellid Co. Ltd is −19.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cellid Co. Ltd (299660)?
The operating margin of Cellid Co. Ltd is −768% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Cellid Co. Ltd (299660) generate?
The free cash flow of Cellid Co. Ltd is −35.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cellid Co. Ltd (299660) carry?
The net debt of Cellid Co. Ltd is 5.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cellid Co. Ltd in the live analysis

One click puts Cellid Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.